Statements (27)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
cannabinoid receptor antagonist |
| gptkbp:affects |
gptkb:endocannabinoid_system
|
| gptkbp:approvedBy |
gptkb:European_Union
|
| gptkbp:ATCCode |
gptkb:A08AX01
|
| gptkbp:CASNumber |
gptkb:168273-06-1
|
| gptkbp:category |
anorectic
anti-obesity agent carboxamides chloroarenes pyrazoles |
| gptkbp:chemicalFormula |
gptkb:C22H21Cl3N4O
|
| gptkbp:developedBy |
gptkb:Sanofi-Aventis
|
| https://www.w3.org/2000/01/rdf-schema#label |
Rimonabant
|
| gptkbp:IUPACName |
5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide
|
| gptkbp:legalStatus |
withdrawn
|
| gptkbp:mechanismOfAction |
CB1 receptor antagonist
|
| gptkbp:molecularWeight |
463.8 g/mol
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
gptkb:depression
anxiety suicidal ideation |
| gptkbp:synonym |
gptkb:SR141716
|
| gptkbp:usedFor |
obesity
|
| gptkbp:withdrawn |
2008
|
| gptkbp:bfsParent |
gptkb:SR141716A
|
| gptkbp:bfsLayer |
7
|